Loading company
Just reported
From MaxCyte's results release of November 10, 2026; its quarterly report has since been filed.
Actual
$10.2M
+49% y/y
+40% q/q
Guided
—
No guide given
Actual
-$0.05
Guided
—
No guide given
Actual
-$6M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes MaxCyte is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$131.6BA+
SYKStryker Corp.$117.9BA+
EWEdwards Lifesciences Corporation$61.6BA+
GEHCGE Healthcare Technologies Inc.$37.5BA
GKOSGlaukos Corp$14.5BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now AEWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now AGEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now ABuilt from MaxCyte, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Company outlook: revenue of about $34.5M for Fiscal year 2026 — up 4.5% on a year earlier, slower than the 48.7% just reported
Grade C-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 20 quarters of MaxCyte, Inc.’s grade history. The other 18 go back to March 2022.
